Crohn’s Disease | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2023

Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. Historically, treatment of pediatric CD would begin with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) and then progress to more-potent drugs, such as biologics and/or immunosuppressants. However, this scenario has changed, and more physicians are now prescribing biologics, especially TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira), as first-line therapy for recently diagnosed pediatric CD patients. The non-TNF biologics, including Takeda’s Entyvio and Janssen’s Stelara, may also be prescribed, particularly after anti-TNF failure.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric CD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric CD patients?
• How have Stelara and Entyvio been integrated into the treatment algorithm, and what is their source of business?
• What percentage of pediatric CD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of pediatric CD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Janssen, Takeda, AbbVie, UCB

Key drugs: Humira, Remicade, biosimilar infliximab, Entyvio, Stelara, Cimzia, aminosalicylates, immunosuppressants

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.